USD 1.85
↓ -0.05 (-2.63%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| VRAX | -2.6 | -10.6 | 8.8 | 33.1 | 135.7 | -28.4 | -99.0 | -99.0 | -99.0 | -99.0 |
| S&P 500 | -1.2 | -1.7 | 1.1 | 6.0 | 10.7 | 30.5 | 25.5 | 88.4 | 188.0 | 33184.9 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | VRAX |
| name | Virax Biolabs Group Limited |
| price | 1.85 |
| changes percentage | -2.63 |
| change | -0.05 |
| day low | 1.84 |
| day high | 1.94 |
| year high | 9 |
| year low | 0.60 |
| market cap | 8032619 |
| price avg 50 | 2.15 |
| price avg 200 | 1.54 |
| exchange | NASDAQ |
| volume | 13912 |
| avg volume | 6044235 |
| open | 1.86 |
| previous close | 1.90 |
| eps | -3.36 |
| pe | -0.55 |
| earnings announcement | 2024-11-19T05:00:00.000+0000 |
| shares outstanding | 4341956 |
| timestamp | 2024-11-15 15:36:03 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001885827 | |||
| revenue | 156419 | 8561.0 | 1,727.11 |
| gross profit | 50590 | -1365.0 | 3,806.23 |
| gross profit ratio | 0.32 | -0.16 | 302.85 |
| research and development expenses | 1561965 | 397109 | 293.33 |
| operating expenses | 6547063 | 5731396 | 14.23 |
| interest income | 0 | 15468 | -100.00 |
| interest expense | 26878 | 15468 | 73.77 |
| ebitda | -6609144 | -5442291 | -21.44 |
| ebitdaratio | -42.25 | -669.64 | 93.69 |
| operating income | -6496473 | -5732760 | -13.32 |
| operating income ratio | -41.53 | -669.64 | 93.80 |
| net income | -6733537 | -5457494 | -23.38 |
| net income ratio | -43.05 | -637.48 | 93.25 |
| eps | -3.36 | -5.13 | 34.50 |
| 2024Q4 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001885827 | |||
| revenue | 79919 | 76500 | 4.47 |
| gross profit | 40072 | 10518 | 280.98 |
| gross profit ratio | 0.5 | 0.14 | 264.69 |
| research and development expenses | 1152670 | 409295 | 181.62 |
| operating expenses | 3830322 | 2716741 | 40.99 |
| interest income | 0 | 10114 | -100.00 |
| interest expense | 16764 | 10114 | 65.75 |
| ebitda | -3722775 | -2688500 | -38.47 |
| ebitdaratio | -46.58 | -35.14 | -32.55 |
| operating income | -3790250 | -2706220 | -40.06 |
| operating income ratio | -47.43 | -35.38 | -34.07 |
| net income | -3823885 | -2909652 | -31.42 |
| net income ratio | -47.85 | -38.03 | -25.80 |
| eps | -1.71 | -1.64 | -4.27 |
Revenue Growth: revenue increased to 0 million in 2024Q4 from 0 million in 2024Q2 representing a change of 4.47%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 0 million in 2024Q4 from 0 million in 2024Q2 representing a change of 280.98%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -4 million in 2024Q4 from -3 million in 2024Q2 representing a change of -38.47%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -4 million in 2024Q4 from -3 million in 2024Q2 representing a change of -40.06%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -4 million in 2024Q4 from -3 million in 2024Q2 representing a change of -31.42%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2024Q4 from 0 million in 2024Q2 representing a change of 181.62%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 4 million in 2024Q4 from 3 million in 2024Q2 representing a change of 40.99%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.71 in 2024Q4 from -1.71 in 2024Q2 representing a change of -4.27%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001885827 | |||
| total assets | 5483969 | 9812416 | -44.11 |
| total liabilities | 345194 | 908401 | -62.00 |
| total equity | 5138775 | 8904015 | -42.29 |
| cash and cash equivalents | 3589244 | 9352538 | -61.62 |
| short term investments | 77321 | 49257 | 56.97 |
| long term investments | 0 | 0 | NaN |
| total current assets | 4380252 | 9634013 | -54.53 |
| total non current assets | 1103717 | 178403 | 518.67 |
| total current liabilities | 168849 | 908401 | -81.41 |
| total non current liabilities | 176345 | 0 | NaN |
| common stock | 2574 | 1557.0 | 65.32 |
| retained earnings | -18527997 | -11794460 | -57.09 |
| total debt | 224300 | 146250 | 53.37 |
Total Assets: Total Assets decreased to 5 million in 2024 from 10 million in 2023 representing a change of -44.11%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 5 million in 2024 from 9 million in 2023 representing a change of -42.29%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 4 million in 2024 from 9 million in 2023 representing a change of -61.62%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 4 million in 2024 from 10 million in 2023 representing a change of -54.53%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -19 million in 2024 from -12 million in 2023 representing a change of -57.09%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 0 million in 2024 from 0 million in 2023 representing a change of 53.37%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 0 million in 2024 from 1 million in 2023 representing a change of -62.0%. This indicates a decrease in overall liabilities.
Short Term Investments: Short Term Investments increased to 0 million in 2024 from 0 million in 2023 representing a change of 56.97%. This indicates an increase in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities decreased to 0 million in 2024 from 1 million in 2023 representing a change of -81.41%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024 from 0 in 2023 representing a change of 65.32%. This indicates an increase in ownership interest.
| 2024Q4 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001885827 | |||
| total assets | 5483969 | 7025262 | -21.94 |
| total liabilities | 345194 | 919049 | -62.44 |
| total equity | 5138775 | 6106213 | -15.84 |
| cash and cash equivalents | 3589244 | 5107882 | -29.73 |
| short term investments | 77321 | 97561 | -20.75 |
| long term investments | 0 | 0 | NaN |
| total current assets | 4380252 | 5971172 | -26.64 |
| total non current assets | 1103717 | 1054090 | 4.71 |
| total current liabilities | 168849 | 787022 | -78.55 |
| total non current liabilities | 176345 | 132027 | 33.57 |
| common stock | 2574 | 1812.0 | 42.05 |
| retained earnings | -18527997 | -14802024 | -25.17 |
| total debt | 224300 | 181706 | 23.44 |
Total Assets: Total Assets decreased to 5 million in 2024Q4 from 7 million in 2024Q2 representing a change of -21.94%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 5 million in 2024Q4 from 6 million in 2024Q2 representing a change of -15.84%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 4 million in 2024Q4 from 5 million in 2024Q2 representing a change of -29.73%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q4 from 0 million in 2024Q2 representing a change of -20.75%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 4 million in 2024Q4 from 6 million in 2024Q2 representing a change of -26.64%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -19 million in 2024Q4 from -15 million in 2024Q2 representing a change of -25.17%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 0 million in 2024Q4 from 0 million in 2024Q2 representing a change of 23.44%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 0 million in 2024Q4 from 1 million in 2024Q2 representing a change of -62.44%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 0 million in 2024Q4 from 1 million in 2024Q2 representing a change of -78.55%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q4 from 0 in 2024Q2 representing a change of 42.05%. This indicates an increase in ownership interest.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001885827 | |||
| net change in cash | -5763294 | 9330782 | -161.77 |
| operating cash flow | -6247016 | -4179767 | -49.46 |
| free cash flow | -7411465 | -4358170 | -70.06 |
| capital expenditure | -1164449 | -178403 | -552.71 |
| depreciation and amortization | 103099 | 0 | NaN |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 1011973 | 1734601 | -41.66 |
| accounts payables | -572246 | 33942 | -1,785.95 |
| inventory | -60383 | 20951 | -388.21 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -952497 | -178403 | -433.90 |
| net cash used for investing activites | -1164449 | -178403 | -552.71 |
| debt repayment | -206272 | 146250 | -241.04 |
| common stock issued | 234 | 13654347 | -100.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 1648171 | 13688952 | -87.96 |
| cash at end of period | 3589244 | 9352538 | -61.62 |
| accounts receivables | -217843 | 0 | NaN |
| cash at beginning of period | 9352538 | 21756 | 42,888.32 |
Net Change in Cash: Net Change in Cash decreased to -6 million in 2024 from 9 million in 2023 representing a change of -161.77%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -6 million in 2024 from -4 million in 2023 representing a change of -49.46%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -7 million in 2024 from -4 million in 2023 representing a change of -70.06%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024 from 0 million in 2023 representing a change of -1785.95%. This indicates that the company has increased its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure decreased to -1 million in 2024 from 0 million in 2023 representing a change of -552.71%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2024 from 2 million in 2023 representing a change of -41.66%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2024 from 0 million in 2023 representing a change of nan%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
| 2024Q4 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001885827 | |||
| operating cash flow | -2789353 | -3457663 | 19.33 |
| free cash flow | -3249274 | -4165844 | 22.00 |
| capital expenditure | -459921 | -708181 | 35.06 |
| depreciation and amortization | 85380 | 17719 | 381.86 |
| deferred income tax | 0 | -378836 | 100.00 |
| stock based compensation | 925704 | 86269 | 973.04 |
| accounts receivables | -34482 | -183361 | 81.19 |
| accounts payables | -522986 | -49260 | -961.68 |
| inventory | -35875 | -24508 | -46.38 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -459921 | -708181 | 35.06 |
| net cash used for investing activites | -456268 | -708181 | 35.57 |
| debt repayment | 0 | -146250 | 100.00 |
| common stock issued | 0 | 234.0 | -100.00 |
| common stock repurchased | -85500 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 1726983 | -78812 | 2,291.27 |
| net change in cash | -1518638 | -4244656 | 64.22 |
| cash at end of period | 3589244 | 5107882 | -29.73 |
| cash at beginning of period | 5107882 | 9352538 | -45.39 |
Net Change in Cash: Net Change in Cash increased to -2 million in 2024Q4 from -4 million in 2024Q2 representing a change of 64.22%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -3 million in 2024Q4 from -3 million in 2024Q2 representing a change of 19.33%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -3 million in 2024Q4 from -4 million in 2024Q2 representing a change of 22.0%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q4 from -1 million in 2024Q2 representing a change of 35.06%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2024Q4 from 0 million in 2024Q2 representing a change of 100.0%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 1 million in 2024Q4 from 0 million in 2024Q2 representing a change of 973.04%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024Q4 from 0 million in 2024Q2 representing a change of -961.68%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q4 from 0 million in 2024Q2 representing a change of 81.19%. This suggests that the company is less capable of collecting payments from its customers.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-03-31 | 2023-03-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 0.08 | 0.01 | 867.99 |
| net income per share | -3.36 | -5.13 | 34.63 |
| operating cash flow per share | -3.11 | -3.93 | 20.82 |
| free cash flow per share | -3.69 | -4.1 | 9.90 |
| cash per share | 1.83 | 8.84 | -79.34 |
| book value per share | 2.56 | 8.38 | -69.42 |
| tangible book value per share | 2.54 | 8.21 | -69.10 |
| shareholders equity per share | 2.67 | 8.59 | -68.85 |
| interest debt per share | 0.01 | 0.15 | -91.19 |
| market cap | 1474714.29 | 7391983.78 | -80.05 |
| enterprise value | -1890229.71 | -1814304.22 | -4.18 |
| pe ratio | -0.22 | -1.35 | 83.83 |
| price to sales ratio | 9.43 | 863.45 | -98.91 |
| pocfratio | -0.24 | -1.77 | 86.65 |
| pfcf ratio | -0.2 | -1.7 | 88.27 |
| pb ratio | 0.27 | 0.81 | -66.07 |
| ptb ratio | 0.27 | 0.81 | -66.07 |
| ev to sales | -12.08 | -211.93 | 94.30 |
| enterprise value over ebitda | 0.29 | 0.33 | -14.21 |
| ev to operating cash flow | 0.3 | 0.43 | -30.29 |
| ev to free cash flow | 0.26 | 0.42 | -38.74 |
| earnings yield | -4.57 | -0.74 | -518.45 |
| free cash flow yield | -5.03 | -0.59 | -752.42 |
| debt to equity | 0 | 0.02 | -100.00 |
| debt to assets | 0 | 0.01 | -100.00 |
| net debt to ebitda | 0.51 | 1.69 | -69.90 |
| current ratio | 25.94 | 10.61 | 144.61 |
| interest coverage | -241.7 | -370.62 | 34.78 |
| income quality | 0.93 | 0.77 | 21.03 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 29.37 | 619.98 | -95.26 |
| research and ddevelopement to revenue | 9.99 | 46.39 | -78.47 |
| intangibles to total assets | 0.01 | 0.02 | -50.08 |
| capex to operating cash flow | -0.19 | -0.04 | -336.71 |
| capex to revenue | 7.44 | 20.84 | -64.28 |
| capex to depreciation | 11.29 | 0 | NaN |
| stock based compensation to revenue | 6.47 | 202.62 | -96.81 |
| graham number | 14.21 | 31.49 | -54.87 |
| roic | -1.21 | -0.62 | -95.81 |
| return on tangible assets | -1.24 | -0.57 | -118.74 |
| graham net net | 1.75 | 8.0 | -78.11 |
| working capital | 4211403 | 8725612 | -51.74 |
| tangible asset value | 5089004 | 8725612 | -41.68 |
| net current asset value | 4035058 | 8725612 | -53.76 |
| invested capital | 5364891 | 8904015 | -39.75 |
| average receivables | 108921.5 | 0 | NaN |
| average payables | 102769.5 | 503191 | -79.58 |
| average inventory | 42239 | 22523 | 87.54 |
| days sales outstanding | 508.33 | 0 | NaN |
| days payables outstanding | 157.38 | 5880.16 | -97.32 |
| days of inventory on hand | 208.26 | 886.02 | -76.50 |
| receivables turnover | 0.72 | 0 | NaN |
| payables turnover | 2.32 | 0.06 | 3,636.29 |
| inventory turnover | 1.75 | 0.41 | 325.44 |
| roe | -1.25 | -0.6 | -109.82 |
| capex per share | 0.58 | 0.17 | 245.80 |
ROE: Return on Equity (ROE) decreased to -1.25 on 2024-03-31 from -0.60 on 2023-03-31, representing a change of -109.82%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 25.94 on 2024-03-31 from 10.61 on 2023-03-31, representing a change of 144.61%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.22 on 2024-03-31 from -1.35 on 2023-03-31, representing a change of 83.83%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-03-31 from 0.02 on 2023-03-31, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-03-31 Q4 | 2023-09-30 Q2 | Q/Q change % | |
|---|---|---|---|
| VRAX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.04 | 0.04 | -16.94 |
| net income per share | -1.71 | -1.64 | -4.49 |
| operating cash flow per share | -1.25 | -1.95 | 35.86 |
| free cash flow per share | -1.46 | -2.35 | 37.99 |
| cash per share | 1.64 | 2.93 | -44.00 |
| book value per share | 2.3 | 3.44 | -33.09 |
| tangible book value per share | 2.28 | 3.23 | -29.41 |
| shareholders equity per share | 2.4 | 3.57 | -32.63 |
| interest debt per share | 0.01 | 0.01 | 31.78 |
| market cap | 1641155.77 | 5769673 | -71.56 |
| enterprise value | -1723788.23 | 843497 | -304.36 |
| pe ratio | -0.11 | -0.5 | 78.36 |
| price to sales ratio | 20.54 | 75.42 | -72.77 |
| pocfratio | -0.59 | -1.67 | 64.74 |
| pfcf ratio | -0.51 | -1.38 | 63.53 |
| pb ratio | 0.31 | 0.91 | -66.43 |
| ptb ratio | 0.31 | 0.91 | -66.43 |
| ev to sales | -21.57 | 11.03 | -295.62 |
| enterprise value over ebitda | 0.46 | -0.31 | 247.59 |
| ev to operating cash flow | 0.62 | -0.24 | 353.33 |
| ev to free cash flow | 0.53 | -0.2 | 362.01 |
| earnings yield | -2.33 | -0.5 | -362.02 |
| free cash flow yield | -1.98 | -0.72 | -174.21 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0.9 | 1.83 | -50.67 |
| current ratio | 25.94 | 7.59 | 241.92 |
| interest coverage | -226.09 | -267.57 | 15.50 |
| income quality | 0.73 | 1.19 | -38.62 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 29.03 | 29.73 | -2.35 |
| research and ddevelopement to revenue | 14.42 | 5.35 | 169.58 |
| intangibles to total assets | 0.01 | 0.05 | -82.98 |
| capex to operating cash flow | -0.16 | -0.2 | 19.50 |
| capex to revenue | 5.75 | 9.26 | -37.83 |
| capex to depreciation | 5.39 | 39.97 | -86.52 |
| stock based compensation to revenue | 11.58 | 1.13 | 927.14 |
| graham number | 9.62 | 11.47 | -16.10 |
| roic | -0.71 | -0.43 | -65.54 |
| return on tangible assets | -0.7 | -0.44 | -60.84 |
| graham net net | 1.57 | 2.5 | -37.00 |
| working capital | 4211403 | 5184150 | -18.76 |
| tangible asset value | 5089004 | 5731543 | -11.21 |
| net current asset value | 4035058 | 5052123 | -20.13 |
| invested capital | 5364891 | 6238240 | -14.00 |
| average receivables | 200602 | 91680.5 | 118.81 |
| average payables | 227124 | 284262.5 | -20.10 |
| average inventory | 42445.5 | 24301.5 | 74.66 |
| days sales outstanding | 245.32 | 215.72 | 13.72 |
| days payables outstanding | 103.06 | 557.36 | -81.51 |
| days of inventory on hand | 136.38 | 33.43 | 307.98 |
| receivables turnover | 0.37 | 0.42 | -12.07 |
| payables turnover | 0.87 | 0.16 | 440.79 |
| inventory turnover | 0.66 | 2.69 | -75.49 |
| roe | -0.71 | -0.46 | -55.09 |
| capex per share | 0.21 | 0.4 | -48.36 |
ROE: Return on Equity (ROE) decreased to -0.71 on 2024-03-31 Q4 from -0.46 on 2023-09-30 Q2, representing a change of -55.09%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 25.94 on 2024-03-31 Q4 from 7.59 on 2023-09-30 Q2, representing a change of 241.92%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.11 on 2024-03-31 Q4 from -0.50 on 2023-09-30 Q2, representing a change of 78.36%. Indicating an increase in the relative valuation of the company's stock.
Negative Sentiment: Discounted Cash Flow value is 0.85 which is lower than current price 1.85, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-10-23 07:30:00
LONDON , Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe," said James Foster, CEO of Virax Biolabs.
Sentiment: Positive
Publish Date: 2024-09-16 08:30:00
LONDON , Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) ("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council ("GCC").
Sentiment: Positive
Publish Date: 2024-09-16 08:30:00
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (NASDAQ: VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as well as for non-exclusive distribution throughout Europe.
Sentiment: Positive
Publish Date: 2024-09-09 08:00:00
LONDON , Sept. 9, 2024 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that Chief Operating Officer, Dr Nigel McCracken is presenting at H.C.
Sentiment: Positive
Publish Date: 2024-08-29 09:03:00
LONDON , Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland. The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.
Sentiment: Positive
Publish Date: 2024-08-28 14:18:08
Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations.
Sentiment: Positive
Publish Date: 2024-08-28 07:30:00
LONDON , Aug. 28, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in 13 European countries as well as members of the Gulf Cooperation Council ("GCC") including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom.
Sentiment: Positive
Publish Date: 2024-08-23 16:09:00
LONDON , Aug. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Sentiment: Positive
Publish Date: 2024-08-21 21:30:00
LONDON , Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about August 23, 2024, subject to the satisfaction of customary closing conditions.
Sentiment: Positive
Publish Date: 2024-08-21 10:20:00
CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today, pursuant to its agreement with Virax Biolabs (NASDAQ: VRAX), that it continues to hold the rights to distribute mpox virus real-time PCR detection kits, with exclusive distribution rights in Greece and Cyprus, and non-exclusive distribution rights across Europe. On August 14, 2024, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations.
Sentiment: Negative
Publish Date: 2024-08-19 12:11:21
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
